Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease with a global prevalence of about 55% in people with type 2 diabetes mellitus (T2DM). T2DM, obesity and NAFLD are three closely inter-related pathological conditions. In addition, T2DM is one of the strongest clinical risk factors for the faster progression of NAFLD to non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Increasing evidence suggests that newer classes of glucose-lowering drugs, such as peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter-2 inhibitors, could reduce the rates of NAFLD progression. This narrative review aims to briefly summarize the recent results from randomized controlled trials testing the efficacy and safety of old and new glucose-lowering drugs for the treatment of NAFLD or NASH in adults both with and without coexisting T2DM.
Citations
Citations to this article as recorded by
Association between goiter and type 2 diabetes in a Chinese population: a cross-sectional study using CHNS data Jiajia Song, Xiaofang Han, Kemei Liu, Fei Zhai, Dechao Yin, Xiaohuan Zhu, Ting Hu Frontiers in Endocrinology.2026;[Epub] CrossRef
The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment Eleni Michalopoulou, John Thymis, Stamatios Lampsas, George Pavlidis, Konstantinos Katogiannis, Dimitrios Vlachomitros, Eleni Katsanaki, Gavriella Kostelli, Sotirios Pililis, Loukia Pliouta, Aikaterini Kountouri, Ioannis S. Papanikolaou, Vaia Lambadiari, Journal of Clinical Medicine.2025; 14(2): 428. CrossRef
Exploring the Mechanism of Action of GLP-1RAs in the Treatment of Non-Alcoholic Fatty Liver Disease Combined with Diabetes Based on Network Pharmacology 高林 齐 Medical Diagnosis.2025; 15(02): 200. CrossRef
Pathogenesis and Clinical Management of Metabolic Dysfunction-Associated Steatotic Liver Disease Roxana Liana Lucaciu, Sorina Cezara Coste, Adriana Corina Hangan, Mihaela Iancu, Olga Hilda Orășan, Angela Cozma, Sidonia Gog Bogdan, Lucia Maria Procopciuc International Journal of Molecular Sciences.2025; 26(12): 5717. CrossRef
High sensitivity C-reactive protein may be a significant predictor of non-alcoholic fatty liver disease in non-obese adults: A four-year retrospective study Changxi Chen, Jiande Gong, Mengting Li, Shiyu Pan, Guitao Xia, Yuemei Xu, Hongliang Li, Qi Lin Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(12): 104224. CrossRef
MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk Alaa M. Mostafa, Ziyan Pan, Ming-Lung Yu, Necati Örmeci, Yasser Fouad, Mohammed Eslam Hepatic Medicine: Evidence and Research.2025; Volume 17: 75. CrossRef
Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis Rutao Lin, Jianghua Zhou, Qinmei Sun, Xin Xin, Yiyang Hu, Minghua Zheng, Qin Feng Alimentary Pharmacology & Therapeutics.2024; 59(7): 802. CrossRef
Current status and future trends of the global burden of MASLD Lei Miao, Giovanni Targher, Christopher D. Byrne, Ying-Ying Cao, Ming-Hua Zheng Trends in Endocrinology & Metabolism.2024; 35(8): 697. CrossRef
Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled trials Hao Wang, Qianqian Ma, Youpeng Chen, Ling Luo, Junzhao Ye, Bihui Zhong Obesity Reviews.2024;[Epub] CrossRef
Non-alcoholic fatty liver disease: a current challenge of interdisciplinary research E. V. Biryukova Meditsinskiy sovet = Medical Council.2024; (6): 72. CrossRef
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development Farah Khaznadar, Omar Khaznadar, Ana Petrovic, Marija Hefer, Fabian Gjoni, Stefan Gjoni, Justinija Steiner, Martina Smolic, Kristina Bojanic Current Issues in Molecular Biology.2024; 46(7): 6300. CrossRef
AI‐based digital pathology provides newer insights into lifestyle intervention‐induced fibrosis regression in MASLD: An exploratory study Hai‐Yang Yuan, Xiao‐Fei Tong, Ya‐Yun Ren, Yang‐Yang Li, Xin‐Lei Wang, Li‐Li Chen, Sui‐Dan Chen, Xiao‐Zhi Jin, Xiao‐Dong Wang, Giovanni Targher, Christopher D. Byrne, Lai Wei, Vincent W.‐S Wong, Dean Tai, Arun J. Sanyal, Hong You, Ming‐Hua Zheng Liver International.2024; 44(10): 2572. CrossRef
Mechanism of Action of Dihydroquercetin in the Prevention and Therapy of Experimental Liver Injury Hewei Wei, Ting Zhao, Xinglong Liu, Qiteng Ding, Junran Yang, Xiaoyu Bi, Zhiqiang Cheng, Chuanbo Ding, Wencong Liu Molecules.2024; 29(15): 3537. CrossRef
Protective Effects of Plum on Liver and Gut Injury in Metabolic Dysfunction-Associated Fatty Liver Disease Ji-Su Kim, Sun-Mee Hong, Do-Kyun Kim, Young-Eun Cho Nutrients.2024; 16(21): 3760. CrossRef
Metabolic dysfunction-associated fatty liver disease: bridging cardiology and hepatology Xiao-Dong Zhou, Giovanni Targher, Christopher D. Byrne, Michael D. Shapiro, Li-Li Chen, Ming-Hua Zheng Cardiology Plus.2024; 9(4): 275. CrossRef
Association of Dipeptidyl Peptidase-4 Inhibitors Use with Reduced Risk of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Chronic HBV Infection Tzu-I Chen, Fu-Jen Lee, Wan-Lun Hsu, Yong-Chen Chen, Mingchih Chen Cancers.2023; 15(4): 1148. CrossRef
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different? Ho Soo Chun, Minjong Lee Clinical and Molecular Hepatology.2023; 29(2): 377. CrossRef
In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome David S. H. Bell, Terri Jerkins Diabetes, Obesity and Metabolism.2023; 25(11): 3093. CrossRef
Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease Iqra J Mazhar, Mohamed Yasir, Saba Sarfraz, Gandhala Shlaghya, Sri Harsha Narayana, Ujala Mushtaq, Basim Shaman Ameen, Chuhao Nie, Daniel Nechi, Sai Sri Penumetcha Cureus.2023;[Epub] CrossRef
Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD) Iryna Kostitska, Nadia Protas, Liliia Petrovska Diabetes Obesity Metabolic Syndrome.2023; (5): 8. CrossRef
Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives Lei Miao, Giovanni Targher, Christopher D. Byrne, Luca Valenti, Xiaolong Qi, Ming‐Hua Zheng Portal Hypertension & Cirrhosis.2022; 1(1): 57. CrossRef
The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy Bo Yuan, Jichun Ma, Jing Wang, Jinyong Hao Frontiers in Endocrinology.2022;[Epub] CrossRef
First
Prev
